Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $66.00

Posted by Geri Gentry on Aug 15th, 2026

Rapport Therapeutics (NASDAQ:RAPP – Free Report) had its target price hoisted by HC Wainwright from $40.00 to $66.00 in a research note released on Wednesday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Rapport Therapeutics’ Q3 2026 earnings at ($1.36) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, Q1 2027 earnings at ($1.63) EPS, Q2 2027 earnings at ($1.68) EPS, Q3 2027 earnings at ($1.73) EPS, Q4 2027 earnings at ($1.77) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

RAPP has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and set a $65.00 price objective on shares of Rapport Therapeutics in a research report on Wednesday, August 5th. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Finally, William Blair initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.57.

Read Our Latest Stock Report on RAPP

Rapport Therapeutics Stock Up 0.1%

Shares of NASDAQ:RAPP opened at $47.42 on Wednesday. Rapport Therapeutics has a 12-month low of $13.86 and a 12-month high of $49.50. The stock has a market cap of $2.28 billion, a PE ratio of -15.60 and a beta of 0.97. The business has a 50 day moving average of $40.89 and a 200-day moving average of $35.28.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). Equities research analysts expect that Rapport Therapeutics will post -4.09 earnings per share for the current year.

Insider Buying and Selling at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 28,958 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer directly owned 486,108 shares of the company’s stock, valued at approximately $23,338,045.08. This represents a 5.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total value of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares in the company, valued at $251,535,026.25. The trade was a 0.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 72,281 shares of company stock worth $3,269,892. 12.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in RAPP. TRV GP V LLC acquired a new stake in shares of Rapport Therapeutics during the 2nd quarter worth approximately $261,709,477,000. ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the second quarter valued at approximately $155,376,512,000. Goldman Sachs Group Inc. raised its position in Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after purchasing an additional 579,903 shares in the last quarter. BlackRock Inc. bought a new stake in Rapport Therapeutics during the second quarter worth $112,500,000. Finally, Vanguard Group Inc. lifted its stake in Rapport Therapeutics by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after purchasing an additional 191,219 shares during the last quarter.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.